Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + nab-paclitaxel + tislelizumab
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This is a combination regimen consisting of three agents: bevacizumab, nab-paclitaxel, and tislelizumab. Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis and thereby restricting tumor blood supply. Nab-paclitaxel (nanoparticle albumin-bound paclitaxel) is a cytotoxic chemotherapeutic agent that stabilizes microtubules, preventing cell division. Tislelizumab is an immune checkpoint inhibitor targeting programmed cell death protein 1 (PD-1), enhancing the immune system’s ability to recognize and destroy cancer cells. This triple combination has been investigated in phase II clinical trials for first-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) and other solid tumors, aiming to leverage antiangiogenic therapy, cytotoxic chemotherapy, and immunotherapy for synergistic antitumor effects[3].
- Brand names
- Avastin + Abraxane + Tevimbra
- Other names
- BETINA regimen
02
Targets
TUBB (Tubulin (alpha and beta subunits))VEGFA (Vascular endothelial growth factor A)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on bevacizumab + nab-paclitaxel + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + nab-paclitaxel + tislelizumab.